BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

607 related articles for article (PubMed ID: 29269569)

  • 1. Intraindividual Comparison of
    Giesel FL; Will L; Lawal I; Lengana T; Kratochwil C; Vorster M; Neels O; Reyneke F; Haberkon U; Kopka K; Sathekge M
    J Nucl Med; 2018 Jul; 59(7):1076-1080. PubMed ID: 29269569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective intraindividual comparison of 18F-PSMA-7Q and 18F-DCFPyL PET/CT in patients with newly diagnosed prostate cancer.
    Liu Y; Zhang X; Liu J; Zhang J; Xu B
    Nucl Med Commun; 2022 Jun; 43(6):725-730. PubMed ID: 35560134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective Comparison of PET Imaging with PSMA-Targeted
    Rowe SP; Li X; Trock BJ; Werner RA; Frey S; DiGianvittorio M; Bleiler JK; Reyes DK; Abdallah R; Pienta KJ; Gorin MA; Pomper MG
    J Nucl Med; 2020 Feb; 61(2):183-188. PubMed ID: 31451492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repeatability of Quantitative
    Jansen BHE; Cysouw MCF; Vis AN; van Moorselaar RJA; Voortman J; Bodar YJL; Schober PR; Hendrikse NH; Hoekstra OS; Boellaard R; Oprea-Lager DE
    J Nucl Med; 2020 Sep; 61(9):1320-1325. PubMed ID: 31924729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer.
    Dietlein M; Kobe C; Kuhnert G; Stockter S; Fischer T; Schomäcker K; Schmidt M; Dietlein F; Zlatopolskiy BD; Krapf P; Richarz R; Neubauer S; Drzezga A; Neumaier B
    Mol Imaging Biol; 2015 Aug; 17(4):575-84. PubMed ID: 26013479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer.
    Rowe SP; Macura KJ; Mena E; Blackford AL; Nadal R; Antonarakis ES; Eisenberger M; Carducci M; Fan H; Dannals RF; Chen Y; Mease RC; Szabo Z; Pomper MG; Cho SY
    Mol Imaging Biol; 2016 Jun; 18(3):411-9. PubMed ID: 27080322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intra-individual comparison of
    Ferreira G; Iravani A; Hofman MS; Hicks RJ
    Cancer Imaging; 2019 May; 19(1):23. PubMed ID: 31092293
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Wondergem M; van der Zant FM; Knol RJJ; Lazarenko SV; Pruim J; de Jong IJ
    J Nucl Med; 2017 Nov; 58(11):1797-1804. PubMed ID: 28450569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.
    Chen Y; Pullambhatla M; Foss CA; Byun Y; Nimmagadda S; Senthamizhchelvan S; Sgouros G; Mease RC; Pomper MG
    Clin Cancer Res; 2011 Dec; 17(24):7645-53. PubMed ID: 22042970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effects of Monosodium Glutamate on PSMA Radiotracer Uptake in Men with Recurrent Prostate Cancer: A Prospective, Randomized, Double-Blind, Placebo-Controlled Intraindividual Imaging Study.
    Harsini S; Saprunoff H; Alden T; Mohammadi B; Wilson D; Bénard F
    J Nucl Med; 2021 Jan; 62(1):81-87. PubMed ID: 32385167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on
    Werner RA; Bundschuh RA; Bundschuh L; Javadi MS; Leal JP; Higuchi T; Pienta KJ; Buck AK; Pomper MG; Gorin MA; Lapa C; Rowe SP
    J Nucl Med; 2018 Dec; 59(12):1857-1864. PubMed ID: 30190304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraindividual Comparison of
    Dietlein F; Kobe C; Hohberg M; Zlatopolskiy BD; Krapf P; Endepols H; Täger P; Hammes J; Heidenreich A; Persigehl T; Neumaier B; Drzezga A; Dietlein M
    J Nucl Med; 2020 May; 61(5):729-734. PubMed ID: 31628219
    [No Abstract]   [Full Text] [Related]  

  • 14. Prospective Evaluation of
    Song H; Harrison C; Duan H; Guja K; Hatami N; Franc BL; Moradi F; Aparici CM; Davidzon GA; Iagaru A
    J Nucl Med; 2020 Apr; 61(4):546-551. PubMed ID: 31628216
    [No Abstract]   [Full Text] [Related]  

  • 15. Simplified Methods for Quantification of
    Jansen BHE; Yaqub M; Voortman J; Cysouw MCF; Windhorst AD; Schuit RC; Kramer GM; van den Eertwegh AJM; Schwarte LA; Hendrikse NH; Vis AN; van Moorselaar RJA; Hoekstra OS; Boellaard R; Oprea-Lager DE
    J Nucl Med; 2019 Dec; 60(12):1730-1735. PubMed ID: 31000583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective Evaluation of
    Gaur S; Mena E; Harmon SA; Lindenberg ML; Adler S; Ton AT; Shih JH; Mehralivand S; Merino MJ; Wood BJ; Pinto PA; Mease RC; Pomper MG; Choyke PL; Turkbey B
    AJR Am J Roentgenol; 2020 Sep; 215(3):652-659. PubMed ID: 32755168
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of Fasting on
    Wondergem M; van der Zant FM; Vlottes PW; Knol RJJ
    J Nucl Med; 2018 Jul; 59(7):1081-1084. PubMed ID: 29496983
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Ulaner GA; Thomsen B; Bassett J; Torrey R; Cox C; Lin K; Patel T; Techasith T; Mauguen A; Rowe SP; Lindenberg L; Mena E; Choyke P; Yoshida J
    Radiology; 2022 Nov; 305(2):419-428. PubMed ID: 35852431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PSA-Stratified Performance of
    Dietlein F; Kobe C; Neubauer S; Schmidt M; Stockter S; Fischer T; Schomäcker K; Heidenreich A; Zlatopolskiy BD; Neumaier B; Drzezga A; Dietlein M
    J Nucl Med; 2017 Jun; 58(6):947-952. PubMed ID: 27908968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective Evaluation of PSMA-Targeted
    Rowe SP; Campbell SP; Mana-Ay M; Szabo Z; Allaf ME; Pienta KJ; Pomper MG; Ross AE; Gorin MA
    J Nucl Med; 2020 Jan; 61(1):58-61. PubMed ID: 31201249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.